Clinical Trials Logo

Clinical Trial Summary

This study is to evaluate the incidence rate of Major Adverse CardioCerebrovascular Events(MACCE) in Patients with Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the secondary prevention and Esomezol Cap for the prevention of gastrointestinal bleeding.


Clinical Trial Description

This study was a multi-center, prospective, non-interventional, observational study of administering Esomezol Cap for the purpose of preventing gastrointestinal bleeding. Data was collected from patients receiving routine treatment at hospitals in South Korea. Each patient visited the institution according to the protocol that designed the follow-up visits for six months to examine the safety of Esomezol Cap. This study approved by the institutions' IRBs and was conducted in compliance with clinical research ethics regulations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05487560
Study type Observational
Source Hanmi Pharmaceutical Company Limited
Contact
Status Completed
Phase
Start date April 18, 2019
Completion date June 22, 2022